Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3(mut)) acute myeloid leukemia (AML) but seldom reduces FLT3(mut) burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Daver, Naval, Perl, Alexander E., Maly, Joseph, Levis, Mark, Ritchie, Ellen, Litzow, Mark, McCloskey, James, Smith, Catherine C., Schiller, Gary, Bradley, Terrence, Tiu, Ramon V., Naqvi, Kiran, Dail, Monique, Brackman, Deanna, Siddani, Satya, Wang, Jing, Chyla, Brenda, Lee, Paul, Altman, Jessica K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746764/
https://www.ncbi.nlm.nih.gov/pubmed/35849791
http://dx.doi.org/10.1200/JCO.22.00602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746764/
https://www.ncbi.nlm.nih.gov/pubmed/35849791
http://dx.doi.org/10.1200/JCO.22.00602

Ejemplares similares